切换至 "中华医学电子期刊资源库"

中华神经创伤外科电子杂志 ›› 2017, Vol. 03 ›› Issue (02) : 105 -108. doi: 10.3877/cma.j.issn.2095-9141.2017.02.011

所属专题: 文献

综述

脑胶质瘤的治疗进展
陈圣攀1, 左晓坤1, 夏鹰1,()   
  1. 1. 570208 海口,中南大学湘雅医学院附属海口医院神经外科
  • 收稿日期:2016-12-15 出版日期:2017-04-15
  • 通信作者: 夏鹰
  • 基金资助:
    海口市医学重点学科-神经外科(2015-05)

Advances in treatment of brain glioma

Shengpan Chen1, Xiaokun Zuo1, Ying Xia1,()   

  1. 1. Department of Neurosurgery, Haikou Hospital of Xiangya Medical College, Central South University, Haikou 570208, China
  • Received:2016-12-15 Published:2017-04-15
  • Corresponding author: Ying Xia
  • About author:
    Corresponding author: Xia Ying, Email:
引用本文:

陈圣攀, 左晓坤, 夏鹰. 脑胶质瘤的治疗进展[J/OL]. 中华神经创伤外科电子杂志, 2017, 03(02): 105-108.

Shengpan Chen, Xiaokun Zuo, Ying Xia. Advances in treatment of brain glioma[J/OL]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2017, 03(02): 105-108.

脑胶质瘤是颅内最常见的原发性肿瘤。根治性手术加放化疗是治疗胶质瘤的基本手段,但由于其易复发、病死率高,治疗效果并不乐观。近年来,随着人们对胶质瘤的不断研究和认识,提出了基因治疗、免疫治疗、分子靶向治疗等多种治疗方式。本文对胶质瘤的治疗策略及研究进展情况加以阐述。

Glioma is the most common primary intracranial tumor. Radical surgery combined with radiotherapy and chemotherapy are the basic treatment method of glioma, but because of its easy recurrence and high mortality, the treatment effects are not optimistic. With the continuous research and understanding of glioma in recent years, gene therapy, immunotherapy, molecular targeted therapy and other therapies are put forward. This study is aimed to summarize the current treatments in glioma.

[1]
Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012[J]. Neuro Oncol, 2015, 17 suppl 4: iv1-iv62.
[2]
江涛.脑胶质瘤治疗技术与进展[M].北京:人民卫生出版社, 2011: 12.
[3]
《中国中枢神经系统胶质瘤诊断和治疗指南》编写组.中国中枢神经系统胶质瘤诊断与治疗指南(2015)[J].中国医学杂志, 2016, 96(7): 485-509.
[4]
Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomized, controlled trial[J]. Lancet Oncol, 2011, 12(11): 997-1003.
[5]
Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts[J]. Neurosurgery, 2007, 61(5): 935-949.
[6]
Leroy HA, Vermandel M, Lejeune JP, et al. Fluorescence guided resection and glioblastoma in 2015: a review[J]. Lasers Surg Med, 2015, 47(5): 441-451.
[7]
刘明,刘楠,刘晓亮,等.荧光素钠引导辅助下胶质瘤切除的应用[J].中国实验诊断学, 2015, (2): 210-213.
[8]
Su X, Huang QF, Chen HL, et al. Fluorescence-guided resection of high-grade gliomas: a systematic review and meta-analysis[J]. Photodiagnosis Photodyn Ther, 2014, 11(4): 451-458.
[9]
戴宜武,王振光,秦家振.脑胶质瘤研究进展[J].脑胶质瘤治疗进展, 2013, 14(7): 6225-6228.
[10]
杨文涛,于喜贞,李正友,等.胶质瘤综合治疗方法研究进展[J].新乡医学院学报, 2016, 33(1): 70-77.
[11]
李博,莫志海,李钰,等. 96例脑胶质瘤术后放射治疗预后影响因素分析[J].临床军医杂志, 2015, 43(5): 487-489, 492.
[12]
杨森,董立新,付占昭,等.恶性胶质瘤术后三维适形放射治疗的临床疗效及不良反应[J].医学信息, 2015, 28(11): 312-313.
[13]
陈宝师,张伟,张忠,等.成人弥漫性低级别胶质瘤替莫唑胺化疗的临床研究[J].中国肿瘤临床, 2016, 43(17): 753-756.
[14]
Stupp R, Mason WP, van den Bent MJ, et al. Radiotheraphy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med, 2005, 352(10): 987-996.
[15]
Arvold ND, Cefalu M, Wang Y, et al. Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma[J]. J Neurooncol, 2016, Epub ahead of print.
[16]
Zhang CX, Zhao WY, Liu L, et al. A nanostructure of functional targeting epirubicin liposomes modified with aminophenyl glucose and cyclic pentapeptide used for brain glioblastoma treatment[J]. Oncotarget, 2015, 6(32): 32681-32700.
[17]
Capdevila L, Cros S, Ramirez JL, et al. Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation[J]. J Neurooncol, 2014, 117(1): 77-84.
[18]
张倩,曹蓓.胶质瘤的免疫治疗研究进展[J].中华神经医学杂志, 2016, 15(8): 856-859.
[19]
Brower V. Checkpoint blockade immunotherapy for cancer comes of age[J]. J Natl Cancer Inst, 2015, 107(3). pii: djv069.
[20]
Tivnan A, Heilinger T, Lavelle EC, et al. Advances in immunotherapy for the treatment of glioblastoma[J]. J Neurooncol, 2016, Epub ahead of print.
[21]
Wang X, Zhao HY, Zhang FC, et al. Dendritic cell-based vaccine for the treatment of malignant glioma: a systematic review[J]. Cancer Invest, 2014, 32(9): 451-457.
[22]
Polyzoidis S, Tuazon J, Brazil L, et al. Active dendritic cell immunotherapy for glioblastoma: current status and challenges[J]. Br J Neurosurg, 2015, 29(2): 197-205.
[23]
郑丽影,吕红,林赋桂,等.脑胶质瘤治疗策略及其研究进展[J].吉林医药学院学报, 2016, 37(1): 50-53.
[24]
王浩,潘建青,胡继良,等.腺病毒介导的HSV-TK/GCV在Cfos启动子调控下对胶质瘤细胞的杀伤作用[J].中华神经医学杂志, 2015, 14(6): 558-562.
[25]
Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer[J]. Nat Rev Drug Discov, 2004, 3(5): 391-400.
[26]
Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma[J]. N Engl J Med, 2014,370(8): 699-708.
[27]
Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly disgnosed glioblastoma[J]. N Engl J Med, 2014, 370(8): 709-722.
[28]
费帆,何永生.脑胶质瘤分子靶向与优化治疗[J].实用医院临床杂志, 2011, 8(2): 199-201.
[29]
Wang Y, Pan L, Sheng XF, et al. Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: first results in chinese patients[J]. Asia Pac J Clin Oncol, 2014, 12(1): e23-e29.
[30]
Mittal S, Pradhan S, Srivastava T. Recent advances in targeted therapy for glioblastoma[J]. Expert Rev Neurother, 2015, 15(8): 935-946.
[31]
王岩.三芪抗瘤汤治疗脑胶质瘤术后60例临床观察[J].河北中医药学报, 2007, 22(2): 19-20, 22.
[1] 刘世佳, 陶新楠, 史晋宇, 吕文豪, 张亚芬. 乳酸脱氢酶A在乳腺癌中的作用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(03): 175-179.
[2] 刘琴, 刘瀚旻, 谢亮. 基质金属蛋白酶在儿童哮喘发生机制中作用的研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 564-568.
[3] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[4] 林逸, 钟文龙, 李锴文, 何旺, 林天歆. 广东省医学会泌尿外科疑难病例多学科会诊(第15期)——转移性膀胱癌的综合治疗[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 648-652.
[5] 吴伟宙, 王琼仁, 詹雄宇, 郑明星, 李亚县. 广东省医学会泌尿外科疑难病例多学科会诊(第16期)——左肾肉瘤样癌[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 525-529.
[6] 李勇, 彭天明, 王倩倩, 陈育纯, 蒲小勇, 刘久敏. 基于失巢凋亡相关基因的膀胱癌预后模型构建及分析[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(04): 331-339.
[7] 李飞, 郑灶松, 吴芃, 谭万龙. 广东省医学会泌尿外科疑难病例多学科会诊(第16期)——延胡索酸水合酶缺陷型晚期肾细胞癌[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(04): 410-414.
[8] 邓楠, 刘平. 广东省医学会泌尿外科疑难病例多学科会诊(第14期)——左肾盂恶性肿瘤并左肾巨大积液[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(03): 296-299.
[9] 黄兴, 王蕾, 夏丹. 靶向免疫治疗时代下减瘤性肾切除术在转移性肾细胞癌治疗中的价值[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(03): 208-213.
[10] 陈旭, 牛凯, 孙建国. 放疗联合免疫治疗对驱动基因阴性NSCLC的困惑分析及应对策略[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(03): 341-348.
[11] 陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.
[12] 魏妙艳, 徐近. 合并远处转移胰腺癌系统性治疗的梳理和展望[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 644-650.
[13] 张燕, 许丁伟, 胡满琴, 李新成, 李翱, 黄洁. 胆囊癌免疫治疗的知识图谱可视化分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 319-327.
[14] 王龙, 武帅, 王炳智, 郑波, 李文斌, 邹霜梅. 结直肠印戒细胞癌的临床病理特征研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(03): 229-235.
[15] 王昌前, 林婷婷, 宁雨露, 王颖杰, 谭文勇. 光免疫治疗在肿瘤领域的临床应用新进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 575-583.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?